Spots Global Cancer Trial Database for anlotinib hydrochloride
Every month we try and update this database with for anlotinib hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | NCT05539118 | Melanoma | Recombinant hum... Toripalimab Anlotinib hydro... | 18 Years - 75 Years | Xijing Hospital | |
| Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma | NCT03890068 | Soft Tissue Sar... | Anlotinib Hydro... | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma | NCT04736810 | Nasopharyngeal ... | AK105 Cisplatin Gemcitabine Anlotinib hydro... | 18 Years - 75 Years | Akeso | |
| Anlotinib Therapy in Patients With Advanced Lung Cancer. | NCT03940404 | Lung Neoplasms | Anlotinib Hydro... | 18 Years - | First People's Hospital of Hangzhou | |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma | NCT04042597 | Effect of Drugs Quality of Life Chordoma Advanced Cancer | Anlotinib Hydro... | 18 Years - | Peking University People's Hospital | |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | NCT03765775 | Carcinoma Non-small Cell ... Lung Neoplasm | Sintilimab Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| Anlotinib or Penpulimab in Combination With RAI for DTC | NCT04952493 | Thyroid Cancer | Anlotinib hydro... Sodium Iodide I... Penpulimab | 18 Years - | Peking Union Medical College Hospital | |
| Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04002284 | Breast Neoplasm Antineoplastic ... Anlotinib | Anlotinib Hydro... | 18 Years - 75 Years | ChineseAMS | |
| Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC | NCT03998085 | Non-Small Cell ... | Anlotinib Hydro... | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI | NCT04007835 | NSCLC | Anlotinib Hydro... | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma | NCT04157478 | Glioblastoma | Anlotinib Hydro... Radiation thera... Temozolomide | 18 Years - 75 Years | People's Hospital of Guangxi | |
| Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI | NCT04007835 | NSCLC | Anlotinib Hydro... | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006) | NCT03778853 | Advanced Non-sq... | Anlotinib Hydro... | 70 Years - | LanZhou University | |
| Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | NCT04620837 | Small Cell Lung... | Tislelizumab Anlotinib hydro... | 18 Years - 75 Years | ChineseAMS | |
| Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | NCT05996484 | Esophageal Carc... Neoadjuvant The... | Toripalimab Anlotinib hydro... Albumin paclita... Cisplatin | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma | NCT05167994 | Sarcoma,Soft Ti... Extremity Trunk Anlotinib Intensity-modul... Major Wound Com... | Anlotinib hydro... | 18 Years - | ChineseAMS | |
| Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC | NCT04028778 | Lung Cancer, No... | Gefitinib Anlotinib Hydro... Placebo | 18 Years - 75 Years | Sun Yat-sen University | |
| Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | NCT05539118 | Melanoma | Recombinant hum... Toripalimab Anlotinib hydro... | 18 Years - 75 Years | Xijing Hospital | |
| A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer | NCT04809142 | Advanced Biliar... | TQB2450 Injecti... Anlotinib hydro... Oxaliplatin inj... Capecitabine ta... Gemcitabine hyd... | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer | NCT04684017 | SCLC Anlotinib | Anlotinib hydro... Etoposide Carboplatin | 18 Years - 75 Years | Shanghai Chest Hospital | |
| A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma | NCT04822805 | Recurrent High-... | Anlotinib hydro... | 18 Years - | First People's Hospital of Hangzhou | |
| Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer | NCT04012619 | Non-squamous No... Anlotinib | Anlotinib Hydro... | 18 Years - 70 Years | Sichuan University | |
| Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma | NCT05124431 | Renal Cell Carc... | Anlotinib hydro... everolimus | 18 Years - | Fudan University | |
| Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence | NCT04213118 | Hepatocellular ... TACE Anlotinib | Anlotinib Hydro... TACE | 18 Years - 75 Years | First Affiliated Hospital Xi'an Jiaotong University | |
| Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | NCT04192682 | Small Cell Lung... | Anlotinib Hydro... | 18 Years - | Changzhou Cancer Hospital of Soochow University | |
| Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | NCT04080843 | Colorectal Canc... RAS and BRAF Wi... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Neoplasms Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Rectal Diseases | Anlotinib Hydro... Capecitabine Oxaliplatin | 18 Years - 75 Years | Zhejiang University | |
| A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | NCT04172571 | Hepatocellular ... | AK105 Anlotinib Hydro... | 18 Years - 75 Years | Akeso | |
| Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | NCT03703596 | Lung Cancer Lung Cancer Met... | Anlotinib Hydro... Docetaxel | 18 Years - 70 Years | Sichuan Cancer Hospital and Research Institute | |
| A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC | NCT04967625 | Small Cell Lung... | Sintilimab Anlotinib hydro... | 18 Years - | Zhejiang Cancer Hospital | |
| Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI | NCT04007835 | NSCLC | Anlotinib Hydro... | 18 Years - 75 Years | Guangdong Association of Clinical Trials | |
| A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | NCT04111913 | Unresectable St... | Anlotinib Hydro... | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | NCT03945799 | Hepatocellular ... | Anlotinib Hydro... | 18 Years - 75 Years | Zhejiang University | |
| Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | NCT05252078 | Esophageal Squa... Esophageal Neop... Esophageal Dise... Gastrointestina... Gastrointestina... Digestive Syste... Digestive Syste... Neoplasms by Si... Neoplasms by Hi... Neoplasms, Squa... Carcinoma, Squa... | Anlotinib hydro... TQB2450 | 18 Years - | Jiangxi Provincial Cancer Hospital | |
| AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer | NCT05244993 | Breast Neoplasm... | AK105 Anlotinib hydro... Albumin Paclita... | 18 Years - 75 Years | Liaoning Tumor Hospital & Institute | |
| Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | NCT04846452 | Metastatic NSCL... Recurrent NSCLC Advanced Non-Sm... | Sintilimab + An... Sintilimab + An... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma | NCT05232552 | Nasopharyngeal ... | Anlotinib hydro... induction chemo... concurrent chem... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Newly Diagnosed Glioblastoma | NCT04959500 | Glioblastoma | Anlotinib Hydro... Placebo Radiation Thera... Temozolomide | 18 Years - 75 Years | Sun Yat-sen University | |
| Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer | NCT03766490 | Non-Small-Cell ... | Anlotinib Hydro... Gefitinib Icotinib | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04624711 | HER2-negative B... | Eribulin Mesyla... Anlotinib hydro... | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma | NCT03951571 | Soft Tissue Sar... High Grade Sarc... | Anlotinib Hydro... Placebo Oral Ta... | 18 Years - | Fudan University | |
| A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer | NCT04181372 | Stage III Non-s... | Anlotinib hydro... platinum-based ... | 18 Years - 75 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | NCT03765775 | Carcinoma Non-small Cell ... Lung Neoplasm | Sintilimab Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | NCT03765775 | Carcinoma Non-small Cell ... Lung Neoplasm | Sintilimab Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma | NCT05193188 | Chondrosarcoma | Anlotinib hydro... PD-1 inhibitor | 18 Years - 100 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer | NCT04503967 | Gastric Adenoca... Esophageal Squa... | Anlotinib Hydro... | 15 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer | NCT04111913 | Unresectable St... | Anlotinib Hydro... | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer | NCT04624711 | HER2-negative B... | Eribulin Mesyla... Anlotinib hydro... | 18 Years - 80 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | NCT03780283 | Carcinoma Lung Neoplasm Small Cell Lung... | Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule | NCT04223583 | Soft Tissue Sar... | Anlotinib Hydro... | 18 Years - 70 Years | Henan Cancer Hospital | |
| The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | NCT04860700 | Malignant Adren... Malignant Parag... Pheochromocytom... Paraganglioma, ... Paraganglioma, ... | anlotinib hydro... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma | NCT05167994 | Sarcoma,Soft Ti... Extremity Trunk Anlotinib Intensity-modul... Major Wound Com... | Anlotinib hydro... | 18 Years - | ChineseAMS | |
| Anlotinib Therapy in Patients With Advanced Lung Cancer. | NCT03940404 | Lung Neoplasms | Anlotinib Hydro... | 18 Years - | First People's Hospital of Hangzhou | |
| Adjuvant Therapy With Anlotinib for HCC | NCT04947371 | Hepatocellular ... | Anlotinib Hydro... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | NCT04080843 | Colorectal Canc... RAS and BRAF Wi... Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Neoplasms Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Rectal Diseases | Anlotinib Hydro... Capecitabine Oxaliplatin | 18 Years - 75 Years | Zhejiang University | |
| Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer | NCT04503967 | Gastric Adenoca... Esophageal Squa... | Anlotinib Hydro... | 15 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL | NCT05883085 | Pheochromocytom... Paraganglioma | Anlotinib hydro... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Anlotinib Therapy in Patients With Advanced Lung Cancer. | NCT03940404 | Lung Neoplasms | Anlotinib Hydro... | 18 Years - | First People's Hospital of Hangzhou | |
| Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | NCT03765775 | Carcinoma Non-small Cell ... Lung Neoplasm | Sintilimab Anlotinib Hydro... | 18 Years - 75 Years | First Hospital of Shijiazhuang City | |
| A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence | NCT03945799 | Hepatocellular ... | Anlotinib Hydro... | 18 Years - 75 Years | Zhejiang University | |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma | NCT04042597 | Effect of Drugs Quality of Life Chordoma Advanced Cancer | Anlotinib Hydro... | 18 Years - | Peking University People's Hospital | |
| Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib | NCT05007093 | DTC - Different... | Anlotinib hydro... | 18 Years - 100 Years | Peking Union Medical College Hospital | |
| Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer | NCT03766490 | Non-Small-Cell ... | Anlotinib Hydro... Gefitinib Icotinib | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | NCT03703596 | Lung Cancer Lung Cancer Met... | Anlotinib Hydro... Docetaxel | 18 Years - 70 Years | Sichuan Cancer Hospital and Research Institute | |
| Anlotinib or Penpulimab in Combination With RAI for DTC | NCT04952493 | Thyroid Cancer | Anlotinib hydro... Sodium Iodide I... Penpulimab | 18 Years - | Peking Union Medical College Hospital | |
| Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib | NCT05007093 | DTC - Different... | Anlotinib hydro... | 18 Years - 100 Years | Peking Union Medical College Hospital | |
| Anlotinib Therapy in Patients With Advanced Lung Cancer. | NCT03940404 | Lung Neoplasms | Anlotinib Hydro... | 18 Years - | First People's Hospital of Hangzhou |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
